

Thymalfasin

Cat. No.:	HY-P0091	
CAS No.:	62304-98-7	
Molecular Formula:	C ₁₂₉ H ₂₁₅ N ₃₃ O ₅₅	
Molecular Weight:	3108.28	Ac-SDAAVDTSSSEITTKDLKEKKEVVEEAEN
Sequence:	Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn	
Sequence Shortening:	Ac-SDAAVDTSSSEITTKDLKEKKEVVEEAEN	
Target:	Influenza Virus	
Pathway:	Anti-infection	
Storage:	Sealed storage, away from moisture	
	Powder -80°C 2 years	
	-20°C 1 year	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 0.3 mg/mL (0.10 mM; Need ultrasonic and warming)
In Vivo	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (32.17 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description	Thymalfasin is an immunomodulating agent able to enhance the Th1 immune response.
In Vitro	Thymalfasin has been shown to have efficacy in multiple experimental models of immune dysfunction, mainly, infectious diseases such as hepatitis (woodchuck) and influenza (mouse), and cancer such as melanoma (mouse) and colorectal carcinoma (rat) where thymalfasin has shown antitumor effects ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Thymalfasin has been shown to have efficacy in multiple experimental models of immune dysfunction, mainly, infectious diseases such as hepatitis (woodchuck) and influenza (mouse), and cancer such as melanoma (mouse) and colorectal carcinoma (rat) where thymalfasin has shown antitumor effects ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Thromb Haemost. 2023 Feb 2;S1538-7836(23)00082-X.
- Brain Res. 2020 Nov 15;1747:147038.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Lao X et al. A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppression of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects. *Apoptosis*. 2015 Oct;20(10):1307-20.

[2]. Sjogren MH et al. Thymalfasin: an immune system enhancer for the treatment of liver disease. *J Gastroenterol Hepatol*. 2004 Dec;19(12):S69-72.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA